These data strongly suggest that in vitro screening of patient-specific responses to CFTR modulators under infection conditions could prove to be valuable for personalizing combination therapy approaches with the appropriate anti-infectives to improve the efficacy of CFTR modulators in CF patients. The gene discussed is CFTR; the disease is infection.